Long-term disease stabilization during second-line gemcitabine in a refractory metastatic haemangioendothelioma

Anticancer Drugs. 2009 Jan;20(1):73-4. doi: 10.1097/CAD.0b013e32831b9b0b.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antimetabolites, Antineoplastic / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bone Neoplasms / drug therapy*
  • Bone Neoplasms / pathology
  • Bone Neoplasms / surgery
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives*
  • Doxorubicin / administration & dosage
  • Gemcitabine
  • Hemangioendothelioma, Epithelioid / drug therapy*
  • Hemangioendothelioma, Epithelioid / pathology
  • Hemangioendothelioma, Epithelioid / surgery
  • Humans
  • Ifosfamide / administration & dosage
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / secondary
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / secondary
  • Male
  • Scapula / pathology*
  • Scapula / surgery
  • Time Factors
  • Treatment Outcome

Substances

  • Antimetabolites, Antineoplastic
  • Deoxycytidine
  • Doxorubicin
  • Ifosfamide
  • Gemcitabine